MLH1 and adenoma: The risk of advanced adenoma was similar in MSH6 and MLH1 patients, at 7.7% (95% CI 6.0–9.4%) and 9.4% (95% CI 5.4–13.4%), respectively, and significantly lower in MSH2 patients, at 17.8% (95% CI 14.6–21%).